Bioresorbable everolimus-eluting vascular scaffold for patients presenting with non STelevation-acute coronary syndrome: A three-years follow-up1

Incidence, Clinical Presentation, and Predictors of Clinical Restenosis in Coronary Bioresorbable Scaffolds

(2017) Alberto Polimeni et al.   JACC-Cardiovascular Interventions

Characteristics, Predictors, and Mechanisms of Thrombosis in Coronary Bioresorbable Scaffolds

(2017) Tommaso Gori et al.   JACC-Cardiovascular Interventions

Intracoronary platelet and monocyte activation status within platelet-monocyte complexes are determinants of inflammation in ST elevation myocardial infarction1

(2016) B. Majumder et al.   CLINICAL HEMORHEOLOGY AND MICROCIRCULATION

Comparison of endothelium-dependent and -independent vasomotor response after abluminal biodegradable polymer biolimus-eluting stent and persistent polymer everolimus-eluting stent implantation (COMPARE-IT)

(2016) Serban Puricel et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes

(2015) Tommaso Gori et al.   JACC-Cardiovascular Interventions

Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds

(2015) Serban Puricel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease

(2015) Stephen G. Ellis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry

(2015) Robin P. Kraak et al.   EuroIntervention

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry

(2015) Davide Capodanno et al.   EuroIntervention

Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes

(2015) Tommaso Gori et al.   EuroIntervention

Zastosowanie stentów bioresorbowalnych w leczeniu chorych ze stabilną dławicą piersiową oraz ostrymi zespołami wieńcowymi. Doświadczenia polskich ośrodków

(2014) Łukasz Rzeszutko et al.   Kardiologia Polska

Vascular Compliance Changes of the Coronary Vessel Wall After Bioresorbable Vascular Scaffold Implantation in the Treated and Adjacent Segments

(2012) Salvatore Brugaletta et al.   CIRCULATION JOURNAL

Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial

(2012) Manel Sabate et al.   LANCET

Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis

(2011) Patrick W. Serruys et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY